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Abstract Recent studies have indicated that ubiquitously 
expressed molecular chaperones of the heat shock protein 
(Hsp) class may have an additional, nuclear, role in the 
regulation of gene expression. Experiments on cellular transcrip-
tion factors derived from the rat adrenal gland have now shown 
that Hsps modulate in vitro DNA binding activity of the AP-1 
factor. Both Hsc70 (p73) and Hsp70 (p72) were demonstrated to 
exert this effect through a mechanism that appears to be 
independent of both redox, and phosphorylation state. Further 
studies on the effect of Hsps on recombinant Fos/Jun protein 
binding activity indicated that the mechanism of action involves a 
selective attenuation of high affinity c-Fos:c-Jun binding as 
compared with c-Jun homodimer binding activity. Because 
cellular and physiological stress are associated with the induction 
of both AP-1 and Hsps it is apparent that Hsps may play a 
modulatory role in the regulation of AP-1 responsive genes. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
A role for heat shock proteins (Hsp) as molecular chaper-
ones in various extra-nuclear cellular compartments is now 
well established [1,2]. The localization of Hsp in the nucleus 
[3,4], and the demonstration that Hsps control the assembly of 
protein complexes [1] has led to the suggestion that Hsps may 
affect gene expression at the level of transcription through 
modulation of transcription factor (and transcription factor/ 
DNA) complex assembly [5]. Indeed, Hsp70 has been impli-
cated in the oligomerization mechanism of the heat shock 
transcription factor [6]. Hsps are known to associate with 
other nuclear proteins such as p53 [7], and both DNaK, an 
E. coli homologue of Hsp70, and human Hsps have been 
shown to control the stability of p53 DNA binding activity 
in vitro [8]. 
Our laboratory has been studying the regulation of AP-1 
transcription factor activity in the adrenal gland [9] ; unusually 
there is a high constitutive level of AP-1 DNA binding activity 
in the rat adrenal [10] but this activity is also modulated by 
various pharmacological and physiological stimuli including 
stress [11]. A corresponding induction of Hsp expression in 
the rat adrenal gland during stress [12] is interesting in the 
context of the potential nuclear effects of Hsp because adrenal 
AP-1 may represent a physiologically regulated transcription 
factor complex that is influenced by Hsps. Accordingly, we 
have now investigated the basis of such potential interactions 
through an investigation of the effects of Hsp on AP-1 activity 
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in vitro. It has been demonstrated that Hsps modulate both 
adrenal gland-derived, and recombinant AP-1 DNA binding 
activity in vitro, through a mechanism that is selective for 
particular binding complexes. 
2. Materials and methods 
Purified and recombinant Hsps were obtained from StressGen Bio-
technologies (Victoria, ВС, Canada). Recombinant c-Fos and c-Jun 
were synthesized using the TNT coupled reticulocyte lysate system 
(Promega, Madison, WI) using, as templates, rat c-fos (see [13]) and 
rat c-jun [13]. Hsp antibodies were from StressGen (anti-Hsc70 mono-
clonal, 1B5), Affinity Bioreagents (Golden, CO; anti-Hsp70 monoclo-
nal, 3a3) and Amersham International (Arlington Heights, IL; anti-
Hsp72, RPN 1197). A c-Jun antisemiti (N; sc-45X) and a glucocorti-
coid receptor (GR) antiserum (P-20; sci002) were obtained from 
Santa Cruz Biotechnologies Ine, Santa Cruz, CA. Reagents used in 
electrophoretic mobility shift assays (EMSA) were from Promega: 
oligonucleotides and T4 polynucleotide kinase, Boehringer Mannheim 
GmbH (Mannheim, Germany): poly [d(I-C)]) and Amersham: 
[γ-32Ρ]ΑΤΡ. Reagents used in the Western blotting procedure includ-
ing blocking solution (ProtoBlock), and chemiluminescence detection 
reagents (HPRL kit) were from National Diagnostics (Atlanta, GA). 
Secondary antisera (sheep, anti-mouse Ig), molecular weight markers 
(Rainbow) and nitrocellulose membrane (Hybond-N, nitrocellulose) 
were from Amersham. All other reagents were from Sigma (St. Louis, 
MO). 
2.1. Electrophoretic mobility shift analysis 
Whole-cell extracts of rat (Sprague-Dawley) adrenal tissue were 
prepared as described [9,14]. The protein content of the extracts was 
determined using the method of Bradford ([15], Bio-Rad, Hercules, 
CA). Recombinant AP-1 proteins were synthesized in vitro as de-
scribed above. EMSAs of DNA binding activity were performed using 
established protocols [9,14]. EMSA probes were 32P-labelled, double-
stranded oligonucleotides; either an AP-1 consensus element-contain-
ing 21mer 5'-CGCTTGATGAGTCAGCCGGAA-3' (Promega), or a 
SP-1 consensus element-containing 22mer 5'-ATTCGATCGGGGC-
GGGGCGAGC-3' (Promega). The oligonucleotides were labelled 
with [γ-32Ρ]ΑΤΡ using T4 polynucleotide kinase and purified on a 
Sephadex G50 column. The specificity of adrenal AP-1 binding activ-
ity has been determined previously [9], and in the present study the 
specificity of both recombinant AP-1 protein, and adrenal SP-1 bind-
ing activity was determined using a molar excess of either unlabelled 
AP-1 or SP-1 oligonucleotide respectively as competitor. Binding re-
actions were performed with 10 μg of whole-cell extract or an aliquot 
of TNT lysate, 2 μg poly [d(I-C)], 2 μΐ of buffer (50 mM HEPES, pH 
7.9, 0.125 mM DTT (except where indicated), 1% NP-40, 5 mM 
spermidine, 1.5 mM MgCl2, 36% glycerol), and 20000 cpm of labelled 
oligonucleotide. The reactions were incubated on ice for 15 min before 
adding the 32P-labelled oligonucleotide, and then for an additional 15 
min at room temperature (22°C). Except where indicated, Hsps and 
antibodies were incubated with adrenal cell extracts for 1 h at 4°C, 
and 1 h at 22°C, prior to the above-described binding reactions. 
Adrenal protein extracts were de-phosphorylated by treating with 
calf intestinal phosphatase (CIP, 0.05 U, 30°C, 20 min) and then 
inactivating the phosphatase with NaH2P04 (40 μΜ). DNA-protein 
complexes were resolved on 4% non-denaturing polyacrylamide gels at 
10 V/cm in 0.25 XTBE buffer prior to autoradiography. Relative 
amounts of DNA binding activity were estimated by densitometric 
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scanning of appropriately exposed autoradiographs (ImageMaster, 
Pharmacia, Sweden). Statistical comparisons were performed using 
Student's i-test, and significance was accepted for P<0 .05 . 
2.2. Hsp depletion and immunoblotting 
Protein samples were depleted of Hsp using a standard ATP-agar-
ose (A2767, Sigma) binding procedure [16] either in the presence or 
absence of an Hsp binding competitor (free ATP, 20 mM). Equal 
aliquots of either depleted or non-depleted protein samples were taken 
for both EMSA analysis and immunoblotting. For immunoblotting, 
protein samples were denatured (boiled for 3 min, 1:1 with electro-
phoresis sample buffer [17]) and separated on 10% denaturing poly-
acrylamide gels at 10 V/cm. The resolved proteins were then trans-
ferred (mini Trans-Blot cell (Bio-Rad) running at 100 V for 1 h at 
room temperature, in 25 mM Tris-base, 192 mM glycine, 20% meth-
anol) to a nitrocellulose membrane. Immunoblotting was then per-
formed using standard techniques according to the HRPL kit proto-
col. Protein bands were visualized using the chemiluminescence 
reaction (HPRL kit) and compared with protein molecular weight 
standards. 
3. Results 
In accordance with previous observations [9,10], AP-1 
DNA binding activity in whole-cell adrenal gland extracts 
was found to be readily demonstrated using an EMSA (Fig. 
1A). The specificity of AP-1 binding activity in the adrenal 
has been determined in previous studies using both unlabelled 
oligonucleotiodes as competitors, and also various antibodies 
in super-shift experiments that have indicated the presence of 
c-Fos-, c-Jun- and JunD-like immunoreactivities in the bind-
ing complex [9]. 
Hsps (either purified bovine Hsc70 (p73) or recombinant 
human Hsp70 (p72)) were shown to attenuate the level of 
adrenal AP-1 DNA binding activity following incubation 
with the adrenal extract (Fig. 1A). The inhibitory action of 
the Hsps was consistently observed in multiple experiments 
(Fig. IB, P<0 .05 for both Hsc70 and Hsp70, Student's t-
test); the purified Hsc70 (approximately 10% Hsp70; Stress-
Gen data sheet, and see Fig. 3B) was observed to exert a 
consistently greater effect than the recombinant Hsp70 (Fig. 
IB). The effect of the Hsps was also shown to be concentra-
tion-dependent (Fig. 1С). With regard to the concentration of 
Hsp required to elicit effects on in vitro AP-1 binding activity 
(0.7 and 1.4 μΜ, Fig. 1A and C), it should be noted that this 
concentration is comparable to that used for both glucocorti-
coid receptor heterocomplex assembly in vitro (3.1 μΜ) [19], 
and modulation of p53 DNA binding in vitro (3.4 μΜ) [8]. 
AP-1 binding activity is known to be determined by a variety 
of factors [19] including protein content of binding buffer, and 
control experiments were performed using a protein of similar 
molecular weight (BSA) which indicated that the observed 
effect was selective for Hsp (Fig. 1A and B). Similarly, it 
was also demonstrated that addition of the Hsp buffer con-
stituents (StressGen data sheets) alone did not significantly 
modify AP-1 binding (data not shown). The effect of Hsp 
on adrenal DNA binding activity was shown to be at least 
partially selective for AP-1 in a further experiment in which 
adrenal SP-1 binding activity was found to be reduced by only 
17% in the presence of a similar concentration of Hsc70 (Fig. 
2). Selectivity in the action of Hsps on DNA binding activity 
was further indicated by the finding that a non-specific AP-1-
associated band that is observed following prolonged auto-
radiograph exposure (eg. see Fig. 4B), is also not attenuated 
in the presence of Hsc70. 
Fig. 1. Effect of Hsps on AP-1 DNA binding activity. Electropho-
retic mobility shift analysis of rat adrenal whole-cell extract binding 
to a 32P-labelled AP-1 element oligonucleotide following incubation 
with Hsps. A: Lane 1, no addition; lane 2, BSA (1.5 μΜ); lane 3, 
Hsc70 (p73) (1.4 μΜ); lane 4, Hsp70 (p72) (1.4 μΜ). Large arrow 
indicates the AP-1 binding complex, and small arrow indicates free 
probe. B: Quantitative analysis of the effects of Hsps and a control 
protein (BSA) on AP-1 DNA binding activity expressed as a per-
centage of AP-1 binding in the absence of added protein, и = 4 ex-
periments (BSA and Hsp70), « = 6 experiments (Hsc70). C: Dose-de-
pendency of the effect of Hsps on AP-1 DNA binding activity. 
Lane 1, no addition; lane 2, Hsc70 (0.7 μΜ); lane 3, Hsc70 (1.4 
μΜ). Free probe is not shown. 
In order to confirm Hsps as the active inhibitory compo-
nent of the exogenous protein preparations, the effect of Hsp 
antibodies was examined in further experiments. However, 
this approach proved to be inappropriate for blocking the 
effect of Hsps on AP-1 activity because it was found that 
the 3a3 monoclonal antibody, which interacts with both 
Hsp70 and Hsc70, also caused a concentration-dependent at-
tenuation of AP-1 binding activity when used alone (data not 
shown). Similar effects were observed with two other commer-
cially available Hsp antibodies (1B5, and RPN 1197), but 
because a similar effect was also observed using similar dilu-
tions of a GR antiserum (data not shown), it is apparent that 
the effect of Hsp antisera on AP-1 activity may be indirect (see 
Section 4). An alternative strategy was therefore employed in 
which the purified Hsc70 preparation was depleted using 
ATP-agarose [16,18]. Following the ATP-agarose procedure, 
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it was found that the efficacy of Hsc70 in attenuating AP-1 
binding was markedly reduced (although not eliminated), 
whereas a similar procedure performed in the presence of a 
competitor (free ATP) was associated with near normal inhib-
itory activity (Fig. ЗА). Depletion of Hsp was confirmed by 
immunoblotting analysis, and it was shown that the extent of 
depletion accorded with the EMSA results in that Hsp deple-
tion was marked, but not complete, and depletion was also 
not fully competed in the presence of free ATP (Fig. 3B). The 
mechanism by which Hsps modulate in vitro binding of adre-
nal proteins to a DNA element was investigated in further 
experiments. Firstly, it was shown that Hsp alone did not 
exhibit AP-1 element binding activity (data not shown), indi-
cating that Hsps do not directly compete with AP-1 proteins. 
Secondly, because it is well established that AP-1 binding 
activity is subject to redox regulation [19], and it has been 
suggested that Hsps may affect protein structure through a 
redox mechanism [20], we investigated whether the effect of 
Hsps in vitro could be attenuated in the presence of a optimal 
concentration of the reducing agent (5 mM DTT) [19] that is 
included in the EMSA binding buffer. However, although it 
was confirmed that AP-1 activity is upregulated in the pres-
ence of a higher concentration of DTT (see [19]), the inhib-
itory action of Hsc70 was unaffected (Fig. 4A). Thirdly, it was 
shown that in vitro dephosporylation of the adrenal protein 
extract, which caused a marked reduction in DNA binding 
activity (Fig. 4B), also did not affect the inhibitory action of 
Hsc70 (Fig. 4B). 
The adrenal AP-1 binding activity used in the experiments 
described above consists of a complex of Fos and Jun proteins 
[9,10] in which a variety of different Jun: Jun homodimers and 
Fos:Jun hererodimers may be formed, and therefore the 
mechanism of action of Hsps was investigated further using 
specific recombinant proteins (Fig. 5). Initially, we confirmed 
that the total AP-1 binding activity of recombinant c-Jun 
alone was relatively low compared with the binding observed 
in the presence of both c-Jun and c-Fos (Fig. 5A), and be-
Fig. 3. Effect of Hsp on AP-1 DNA binding activity is attenuated 
following depletion. Electrophoretic mobility shift analysis (EMSA) 
of rat adrenal whole-cell extract binding to a 32P-labelled AP-1 ele-
ment oligonucleotide. A: EMSA analysis of the effect of Hsp on 
AP-1 activity following depletion with ATP-agarose (see text). Lane 
1, no addition; lane 2, Hsc70 (p73) (1.4 μΜ), no depletion; lane 3, 
Hsc70 (1.4 μΜ), depleted; lane 4 Hsc70 (1.4 μΜ), depleted in pres-
ence of excess ATP. B: Western blot of equal aliquote of Hsc70 de-
rived from the treatments in B. Lane 1, no depletion; lane 2, de-
pleted; lane 3, depleted in presence of excess ATP. Arrow indicates 
the position of protein molecular weight marker. 
cause c-Fos alone did not exhibit detectable binding activity 
(data not shown), it is apparent that the increased activity is 
due to the formation of higher affinity c-Fos:c-Jun hetero-
dimers as demonstrated in previous studies [21,22]. It should 
be noted that the binding complex formed in the presence of 
c-Jun alone migrates relatively slowly compared with the c-
Fosx-Jun complex (as observed previously) [21], and that 
using shorter EMSA autoradiograph exposures of c-Fos :c-
Jun mixtures, the two complexes can be resolved (see Fig. 
5C, lane 3). In confirmation of Fos:Jun heterodimer forma-
tion, we also showed that the enhanced binding activity of c-
Fos: c-Jun mixtures was fully super-shifted in the presence of 
an antiserum to c-Jun (Fig. 4B). The specificity of recombi-
nant protein binding was further confirmed by competition 
with unlabelled AP-1 oligonucleotide which markedly reduced 
the binding activity (Fig. 5A) whereas a similar molar excess 
of the SP-1 oligonucleotide exhibited only a minor effect (data 
not shown). Following addition of Hsc70 to the recombinant 
protein binding assays, it was found that AP-1 binding activ-
ity was attenuated but that the effect was selective for Fos:Jun 
heterodimers as compared with the binding associated with 
Jun alone (Fig. 5C). Thus, using short exposures of the 
EMSA autoradiographs (Fig. 5C) it was shown that the faster 
migrating c-Fos-associated band was reduced by 50% in the 
presence of Hsc70 whereas the binding of c-Jun alone was not 
significantly inhibited. 
4. Discussion 
Fig. 2. Effect of Hsps on SP-1 DNA binding activity. Electrophoret-
ic mobility shift analysis of rat adrenal whole-cell extract binding to 
a 32P-labelled SP-1 element oligonucleotide following incubation 
with Hsc70 (p73). Lane 1, no addition; lane 2, binding reaction per-
formed in presence of a 50 M excess of unlabelled SP-1 oligonucleo-
tide; lane 3, Hsc70 (1.4 μΜ). Large arrow indicates the major SP-1 
binding complex. Small arrow indicates free probe. 
AP-1, a variable complex of Fos and Jun family proteins 
that exhibits cell-type and activation-dependent specificity, is 
an important transcription factor that has been implicated in 
numerous developmental, physiological and pathological 
processes [23-27]. While it is clear that de novo induction of 
AP-1 is an important mechanism by which AP-1 activity is 
controlled [23], recent studies have increasingly shown that 
AP-1 is subject to other modes of regulation that include 
inhibitory interactions with other transcription factors (see 
below), and chemical modifications such as reduction by cel-
lular redox factors [19] and phosphorylation [28]. We have 
now provided evidence to show that AP-1 DNA binding ac-
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tivity, which is one determinant of transcriptional activation 
potential, is modulated by the ubiquitously expressed Hsps. 
Although Hsps are known to be active in extra-nuclear com-
partments, there is substantial evidence to show that Hsps are 
also active in the nucleus [3-8]. In addition Hsps are known to 
be induced following stimuli that also induce AP-1. For ex-
ample, Hsp70 is markedly induced in the rat brain following 
epileptic seizures [29], a stimulus that is also associated with 
induction of AP-1 [23]. In relation to the present study of 
adrenal AP-1, expression of both Hsp and AP-1 is increased 
in the adrenal cortex following restraint stress [11,12]. When 
considered in the light of the present findings, these studies 
indicate that one of the roles of Hsp may be to modulate the 
functional consequences of a change in AP-1 activity through 
regulated attenuation of DNA binding activity. Following 
seizure-related Hsp70 (p72) induction in the brain such a 
role would appear to be non-acute given the delayed temporal 
profile of Hsp induction [29], but the rapid onset of stress-
induced Hsp induction in the adrenal [12] may indicate a more 
acute modulatory interaction of induced Hsps and AP-1 tran-
scription factors. Alternatively, the constitutively expressed 
Hsc70 is known to be rapidly relocated into the nucleus fol-
lowing cellular stress [4], and the potent modulatory effects of 
Hsc70 demonstrated in the present study indicate that induc-
tion of the 'stress-specific' Hsp70 (p72) is not necessarily re-
quired for a potentially rapid modulation of AP-1 activity via 
Hsps. Following the in vitro studies described here, in vivo 
approaches are now required to investigate the physiological 
relevance of these possibilities. In the case of the adrenal 
Fig. 5. Hsps exhibit selective inhibition of c-Fos:c-Jun heterodimer 
binding activity. Electrophoretic mobility shift analysis (EMSA) of 
recombinant c-Jun (1 ul of rat c-jun-primed reticulocyte lysate) and 
c-Fos (1 ul rat c-fos-primed reticulocyte lysate) binding to a 32P-la-
belled AP-1 element oligonucleo tide. A: EMSA analysis of c-Jun 
(lanes 1 and 2) or c-Jun plus c-Fos (lanes 3 and 4) binding activity. 
The binding reactions of lanes 2 and 4 contained a 50 M excess of 
unlabelled AP-1 oligonucleotide. Free probe is not shown. (Note 
that lysate primed with c-fos alone exhibited no detectable AP-1 
binding activity; not shown.) B: EMSA analysis of c-Jun plus c-Fos 
binding activity following incubation with either no antibody (lane 
1), a c-Jun antibody (lane 2; 2 ul IgG) or a control antibody (lane 
3; sheep, anti-mouse Ig; 2 ul). Arrow indicates the origin. C: 
EMSA analysis of either c-Jun (lanes 1 and 2) or c-Jun plus c-Fos 
(lanes 3 and 4) binding activity following incubation with Hsp. 
Lane 1, no addition; lane 2, Hsc70 (p73) (1.4 μΜ); lane 3, no addi-
tion; lane 4, Hsc70 (p73) (1.4 μΜ). Free probe is not shown. Ar-
rows indicate the position of the two resolved EMSA bands in lanes 
3 and 4. 
Fig. 4. Effect of Hsp on AP-1 DNA binding activity is not modified 
following either redox modification or dephosphorylation of AP-1 
activity. A: Electrophoretic mobility shift analysis (EMSA) of rat 
adrenal whole-cell extract binding to a 32P-labelled AP-1 element 
oligonucleotide in the presence of either 0.125 mM DTT (lanes 1 
and 2) or 5 mM DTT (lanes 3 and 4). Lane 1, no addition; lane 2, 
Hsc70 (p73) (1.4 μ,Μ); lane 3, no addition; lane 4, Hsc70 (p73) (1.4 
μΜ). Free probe is not shown. В : EMSA analysis of either control-
treated (lanes 1 and 2) or dephosphorylated (lanes 3 and 4) rat 
adrenal whole-cell extract binding to a 32P-labelled AP-1 element 
oligonucleotide in either the presence or absence of Hsp. Lane 1, no 
addition; lane 2, Hsc70 (p73) (1.4 μΜ); lane 3, no addition; lane 4, 
Hsc70 (p73) (1.4 μΜ). Free probe is not shown. Note that the auto-
radiograph has been over-exposed with respect to the binding activ-
ity in lanes 1 and 2. Arrow indicates a non-specific AP-1-associated 
band. 
gland, it is apparent that AP-1 responsive genes such as pro-
enkephalin [30] may be subject to regulation by Hsps. 
The modulation of AP-1 binding activity by Hsp does not 
involve a direct competition for DNA binding, and also does 
not appear to involve a redox [18,20] or de-phosphorylation 
(see [28]) mechanism. It is reasonable to speculate that the 
modulatory activity demonstrated here is related to the char-
acterized function of Hsps as chaperones that influence the 
assembly of protein complexes [2]. Thus, the integrity of cel-
lular AP-1 factors, which are composed of a variable complex 
of Fos:Jun heterodimers, and JunrJun homodimers that ex-
hibit different DNA binding affinities [31] may be dependent 
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on a local influence of Hsps. Our finding that Hsps appear to 
selectively attenuate the binding of high affinity Fos:Jun het-
erodimers as compared with Jun:Jun homodimers has pro-
vided a mechanistic basis for the demonstrated reduction in 
AP-1 binding activity by Hsps. A selective attenuation of 
Fos:Jun heterodimer formation would be biologically signifi-
cant in that the transcriptional activity of c-Fos and c-Jun 
together is markedly greater than either factor alone [32,33]. 
That the attenuation of c-Jun:c-Fos binding activity by Hsp 
was found to be somewhat less marked than the attenuation 
of adrenal AP-1 activity, may be explained by the presence of 
alternative heterodimeric binding complexes in the adrenal 
extract, for example JunD:c-Fos [9]. With respect to interact-
ing protein complexes other than AP-1, it has been shown 
that over-expression of Hsp70 can negatively influence the 
stability of heat shock transcription factor (HSF) trimers 
(see [6]). Hsps might affect transcription factor binding at 
the level of protein:DNA interaction because it has been sug-
gested that local folding transitions which are coupled to 
DNA binding [34] may be influenced by Hsps [5]. A similar 
mode of regulation may underlie the effect of Hsp70 on estro-
gen receptor (ER)/estrogen response element (ERE) stability 
that appears to be due to an increase in the association rate of 
ER with ERE [35], and also the effect of Hsps on p53/DNA 
complex stability [8]. An interesting corollary of the present 
findings relates to the interaction of Hsp70 with the glucocor-
ticoid receptor (GR) complex (see [15]) because recent studies 
have revealed complex regulatory interactions between GR 
and AP-1 [36,37]. In addition to the implication of a func-
tional role in stress-related gene expression (see above), the 
present findings may also relate to other cellular mechanisms 
that involve AP-1; for example, a post-transcriptional attenu-
ation of AP-1 activity is associated with some forms of neuro-
nal cell death [38]. 
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